Research on cancer vaccines published by scientists at Memorial Sloan Kettering Cancer Center
2007 NOV 19 -- Fresh data on cancer are presented in the report 'A polyvalent vaccine for high-risk prostate patients: "are more antigens better?".' According to a study from the United States, "We have shown the immunogenicity and safety of synthetic carbohydrate vaccines when conjugated to the carrier keyhole limpet hemocyanin (KLH) and given with the adjuvant, QS-21, in patients with biochemically relapsed prostate cancer. To determine whether immune response could be further enhanced with stimulation by multiple antigens, a hexavalent vaccine was prepared using previously determined doses and administered in a Phase II setting to 30 high-risk patients." "The hexavalent vaccine included GM2, Globo H, Lewis(y), glycosylated MUC-1-32mer and Tn and TF in a clustered formation, conjugated to KLH and mixed with QS-21. Eight vaccinations were administered over 13 months. All 30 patients had significant elevations in antibody titers to at least two of the six antigens; 22 patients had increased reactivity with FACS. These serologic responses were lower than that seen previously in patients treated with the respective monovalent vaccines. The reciprocal median combined IgM and IgG antibody titers with ELISA against MUC1, Tn, TF, globo H and GM2 for these 30 patients were 640, 80, 120, 40 and 0, compared to 1280, 640, 1280, 320 and 160 seen in patients receiving individual monovalent vaccines. This hexavalent vaccine of synthetic 'self' antigens broke immunologic tolerance against two or more antigens in all 30 vaccinated patients, was safe, but antibody titers against several of the antigens were lower than those seen in individual monovalent trials. No impact on PSA slope was detected," wrote S.F. Slovin and colleagues, Memorial Sloan Kettering Cancer Center. The researchers concluded: "We address the relevance of the multivalent approach for prostate cancer treatment." Slovin and colleagues published the results of their research in Cancer Immunology, Immunotherapy (A polyvalent vaccine for high-risk prostate patients: "are more antigens better?" Cancer Immunology, Immunotherapy, 2007;56(12):1921-30). For additional information, contact S.F. Slovin, Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York City, NY 10021 USA.. The publisher of the journal Cancer Immunology, Immunotherapy can be contacted at: Springer, 233 Spring Street, New York, NY 10013, USA. Keywords: United States, New York, Biological Therapy, Biotechnology, Cancer Vaccines, Immunization, Immunology, Immunotherapy, Oncology, Polyvalent Vaccines, Treatment, Vaccination. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2007, Biotech Business Week via NewsRx.com.
|
